/
PDSB
$0.90+$0.01 (+1.19%)prev close
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$49.6M
56M shares
52-week range
$0.51 – $1.55
38% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.37%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-11.48
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $69.1K | $98.4K | $0 | $0 | $0 | $57.3K | $59.8K | $0 |
| Gross profit | −$69.1K | −$98.4K | $0 | $0 | $0 | −$57.3K | −$59.8K | $0 |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $830.7K | $6.1M | $7.9M | $11.3M | $29.4M | $27.8M | $22.6M | $19.0M |
| Operating income | −$43.1M | −$15.5M | −$14.9M | −$21.4M | −$41.7M | −$43.0M | −$36.3M | −$31.5M |
| EBITDA | −$3.6M | −$7.2M | −$14.9M | −$21.4M | −$40.7M | −$40.1M | −$33.7M | −$30.3M |
| Net income | −$40.9M | −$7.0M | −$14.8M | −$16.9M | −$40.9M | −$42.9M | −$37.6M | −$34.5M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -10.25 | -1.44 | -0.89 | -0.66 | -1.43 | -1.39 | -1.03 | -0.74 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $11M | $-0.50 | $-0.57–$-0.42 | 2 |
| 2027 | $23M | $-0.47 | $-0.57–$-0.36 | 2 |
| 2028 | $4M | $-0.42 | $-0.49–$-0.35 | 3 |
| 2029 | $93M | $0.50 | $0.50–$0.50 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.14
Price
$0.90
Implied downside
-84%
Peer comparison
PDS Biotechnology Corporation Common Stock
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.
www.pdsbiotech.com- Employees
- 21
- IPO / List date
- Oct 1, 2015
- HQ
- PRINCETON, NJ
Held by traders on TradeandTell
No one on the platform currently holds PDSB.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 220,800 | $133.6K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded PDSB yet.
